ALX Oncology Holdings Inc. (ALXO) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-09

How it makes money

It currently generates no revenue and relies on equity financing to fund the development of its experimental cancer drug candidates.

As a clinical-stage biotechnology company, it has not yet commercialized any products. Its financial model is entirely dependent on successfully completing clinical trials to gain regulatory approval, after which it intends to license or market therapies directly to healthcare systems.

What protects it: the moat

Management claims its proprietary inactivated Fc domain protects its therapies from the toxic side effects found in competing CD47-blocking treatments.

The company asserts that its fusion protein design avoids the depletion of healthy blood cells that often limits the dosing window of competing products, potentially allowing for higher efficacy in solid tumors.

What growth costs

It must aggressively reinvest almost all capital into expensive, multi-year clinical trials to determine if its molecules are safe and effective.

Research and development costs remain the primary driver of its capital requirements, necessitating significant periodic cash outflows for patient recruitment, trial administration, and manufacturing of clinical-grade test supplies.

What could damage it

Failure to demonstrate superior clinical efficacy over existing standards of care would render its pipeline worthless, as no market for its specific therapies would materialize.

Because its business model is predicated on being a 'next-generation' improvement over current oncology drugs, a trial failure or refusal by regulators to grant approval would cause an immediate and permanent loss of its ability to monetize its core intellectual property.

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Other companies in Biotechnology